Published online Apr 7, 2018. doi: 10.3748/wjg.v24.i13.1398
Peer-review started: January 28, 2018
First decision: February 10, 2018
Revised: February 12, 2018
Accepted: March 3, 2018
Article in press: March 3, 2018
Published online: April 7, 2018
Ulcerative colitis (UC), as a recurrent chronic inflammatory disease, greatly affects the quality of life of patients, which brings an enormous challenge for both individuals and society worldwide. However, the etiology of UC is still unknown and conventional medical treatments for UC are not fully curative. Thus, promising and novel therapeutic strategies are imperatively needed and should be explored for UC.
Inflammation is a major factor for the progression of UC, and studies have confirmed that a great deal of natural medicines are intended for inhibition of various chronic inflammation-associated diseases, such as Ampelopsis grossedentata (AMP). Thus, we explored the mechanisms of therapeutic effects of AMP on UC, and provided a valid complementary treatment to the standard therapy.
To investigate the underlying mechanisms of protective effects of AMP on dextran sulfate sodium (DSS)-induced colitis.
As an emerging approach, systems pharmacology was performed in this study to explore the systematic effects of AMP on DSS-induced colitis by active compound screening, target fishing, network construction and analysis.
The study revealed an antiinflammatory effect of AMP against DSS-induced colitis based on systems pharmacology and animal experiments.
AMP could exert beneficial effects on DSS-induced colitis via suppressing inflammation-related signaling pathways.
Since UC is an inflammatory condition combined with a large amount of other biological processes, we determined the inflammatory-related signaling pathways in this study. Other biological processes and signaling pathways as well as the systematic effects of AMP on UC were still unknown and need to be explored in further studies.